Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies
The results of the studies were detailed by Dr Nancy Sullivan, head of the VRC's Biodefense Research Section, at a scientific meeting held at USAMRIID in Fort Detrick, Maryland.
"The timely execution of a series of complex vaccine studies with our Ebola vaccine proves the viability and agility of public-private partnerships such as that between Crucell and the VRC," said Crucell's Chief Scientific Officer, Dr Jaap Goudsmit. "The combination of the VRC's Ebola know-how, USAMRIID's ability to perform Ebola-challenge studies and Crucell's vaccine technology was the key to the current success. It augurs well for the field of biodefense, and for future responses to potential infectious disease outbreaks such as the current Marburg crisis."
Crucell recently secured an exclusive license to patents of the NIH for the development and commercialisation of recombinant vaccines against Ebola.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.